Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.

Michael KurnellasAnanya MitraTina SchwabeRobert PaulAndrew E ArrantErik D RobersonMichael WardFelix YehHua LongArnon Rosenthal

Published in: Journal of translational medicine (2023)

These findings support the development of latozinemab for the treatment of FTD-GRN and other neurodegenerative diseases where elevation of PGRN may be beneficial. Trial registration ClinicalTrials.gov, NCT03636204. Registered on 17 August 2018, https://clinicaltrials.gov/ct2/show/NCT03636204 .

Keyphrases

computed tomography
clinical trial
study protocol
magnetic resonance imaging
dual energy
contrast enhanced
phase ii
positron emission tomography
open label